Kerem Therapeutics

Harnessing The Power Of The Immune System

Kerem Therapeutics
Kerem (keh'-rem): "vineyard" or "orchard"
Symbolizing abundance, prosperity, and fertility,

two people in a vineyard celebrating life after immune system tumor and cancer treatments like RIB-001 and RIX-001

About Kerem Therapeutics

Our Biotech Mission

Kerem Therapeutics is a clinical stage biotechnology company developing and distributing conditionally approved cell-based immunotherapies for multiple solid tumor indications. Our first commercial product is RBI-001, a highly differentiated, first-in-class autologous cell product composed of Tat-MYC treated peripheral blood mononuclear cells (PBMCs). In addition, we are launching a clinical trial for RIX-001, a version of Tat- MYC treated PBMCs that are manufactured at the bedside in real time for immediate reinfusion into the patient. Treatment of PBMCs with Tat-MYC has been shown to transiently reverse lymphoid anergy and enable anti-solid tumor activity of the immune system.

Kerem Therapeutics, cell-based immunotherapies for multiple solid tumor indications

Cell Based Immunotherapy Product

RBI-001 consists of autologous PBMCs treated ex-vivo with Tat-MYC protein.
This process reverses lymphoid cell anergy to self-antigens. The short incubation of
PBMCs with Tat-MYC appears to provide the cells with a signal similar to that which is
normally derived from the IL-2 receptor allowing us to provide the therapeutic benefits of
IL-2 without any of the untoward side effects.

Current Clinical Use

RIB-001 is conditionally approved under a self-pay program in Japan by the Japanese Ministry of Health, Labor and Welfare for use in patients with cancer, chronic viral infections and healthy patients wanting to boost their immune function. RIB-001 is currently available in 3 clinics in Japan located in Tokyo and Sendai.